Time in tight glucose range in adolescents and young adults with diabetes during Ramadan intermittent fasting: Data from real-world users on different treatment strategies

被引:0
作者
Elbarbary, Nancy Samir [1 ]
Ismail, Eman Abdel Rahman [2 ]
机构
[1] Ain Shams Univ, Fac Med, Diabet & Endocrine Unit, Dept Pediat, Cairo, Egypt
[2] Ain Shams Univ, Fac Med, Dept Clin Pathol, Cairo, Egypt
关键词
Type; 1; diabetes; 2; Time in range; Time in Tight Range; Continuous glucose monitoring; Advanced hybrid closed-loop system; Sensor augmented pump; Multiple daily injections; Ramadan Intermittent Fasting; MULTIPLE DAILY INJECTIONS; INSULIN PUMP; GLYCEMIC CONTROL; TYPE-1; CHILDREN; DEFINITION; SYSTEM;
D O I
10.1016/j.diabres.2025.112042
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Time in tight range (TITR) is a novel glycemic metric assessing normoglycemia in individuals with diabetes. Aim: To assess the attainability of the TITR (70-140 mg/dL) target in youth with diabetes using different treatment strategies during Ramadan fasting. Methods: This prospective study included 276 non-insulin-treated type 2 diabetes mellitus (T2DM) and 426 patients with type 1 diabetes mellitus (T1DM) who were categorized into: multiple daily injections [MDI] + intermittently scanned CGM (isCGM), sensor augmented pump (SAP) and advanced hybrid closed loop (AHCL). Results: At the end of Ramadan, the mean TITR was 42.3 +/- 6.6 % for all T1DM patients and 63.5 +/- 4.0 % in T2DM (p G 0.001). The highest TITR was in T2DM group together with T1DM on AHCL (62.3 +/- 11.6 %), followed by SAP group (37.7 +/- 5.7 %) and MDI + isCGM group (23.6 +/- 5.9 %, p G 0.001). Hypoglycemic episodes as shown by time below range (TBR) G 70 mg/dL and TBR G 54 mg/dL were minimal during Ramadan in AHCL group in comparison to before Ramadan (2.6 +/- 0.7 versus 2.9 +/- 0.9 %; p = 0.061 and 0.4 +/- 0.1 vs 0.5 +/- 0.1 %, p = 0.561, respectively) with a lower coefficient of variation (CoV) (p G 0.001) than other T1DM participants. Conclusion: At the end of Ramadan, TITR was decreased in patients with T1DM except those using AHCL who had similar levels to non-insulin-treated T2DM patients. Advanced technology has the potential for achieving tight glycemic targets, along with a reduction in CoV, without increasing hypoglycemic risk compared with other insulin treatment modalities.
引用
收藏
页数:10
相关论文
共 72 条
  • [11] Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population
    Alonso, G. Todd
    Triolo, Taylor M.
    Akturk, Halis Kaan
    Pauley, Meghan E.
    Sobczak, Marisa
    Forlenza, Gregory P.
    Sakamoto, Casey
    Pyle, Laura
    Frohnert, Brigitte I.
    [J]. DIABETES CARE, 2023, 46 (06) : 1218 - 1222
  • [12] Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users
    Arrieta, Arcelia
    Battelino, Tadej
    Scaramuzza, Andrea E.
    Da Silva, Julien
    Castaneda, Javier
    Cordero, Toni L.
    Shin, John
    Cohen, Ohad
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (07) : 1370 - 1379
  • [13] Bahijri S, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0060917, 10.1371/annotation/8d92315c-9944-4470-9bbb-806a26b0809b]
  • [14] Utility of time in tight range (TITR) in evaluating metabolic control in pediatric and adult patients with type 1 diabetes in treatment with advanced hybrid closed-loop systems
    Bahillo-Curieses, Pilar
    Fernandez Velasco, Pablo
    Perez-Lopez, Paloma
    Vidueira Martinez, Ana Maria
    Nieto de la Marca, Maria de la O.
    Diaz-Soto, Gonzalo
    [J]. ENDOCRINE, 2024, 86 (02) : 539 - 545
  • [15] Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
    Battelino, Tadej
    Bergenstal, Richard M.
    Rodriguez, Angel
    Fernandez Lando, Laura
    Bray, Ross
    Tong, Zhentao
    Brown, Katelyn
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (06) : 407 - 417
  • [16] Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
    Battelino, Tadej
    Danne, Thomas
    Bergenstal, Richard M.
    Amiel, Stephanie A.
    Beck, Roy
    Biester, Torben
    Bosi, Emanuele
    Buckingham, Bruce A.
    Cefalu, William T.
    Close, Kelly L.
    Cobelli, Claudio
    Dassau, Eyal
    DeVries, J. Hans
    Donaghue, Kim C.
    Dovc, Klemen
    Doyle, Francis J.
    Garg, Satish
    Grunberger, George
    Heller, Simon
    Heinemann, Lutz
    Hirsch, Irl B.
    Hovorka, Roman
    Jia, Weiping
    Kordonouri, Olga
    Kovatchev, Boris
    Kowalski, Aaron
    Laffel, Lori
    Levine, Brian
    Mayorov, Alexander
    Mathieu, Chantal
    Murphy, Helen R.
    Nimri, Revital
    Norgaard, Kirsten
    Parkin, Christopher G.
    Renard, Eric
    Rodbard, David
    Saboo, Banshi
    Schatz, Desmond
    Stoner, Keaton
    Urakami, Tatsuiko
    Weinzimer, Stuart A.
    Phillip, Moshe
    [J]. DIABETES CARE, 2019, 42 (08) : 1593 - 1603
  • [17] Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes
    Beato-Vibora, Pilar Isabel
    Gallego-Gamero, Fabiola
    Ambrojo-Lopez, Ana
    Gil-Poch, Estela
    Martin-Romo, Irene
    Arroyo-Diez, Francisco Javier
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (09) : 609 - 615
  • [18] A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70-180 mg/dL Versus Time-in-Tight-Range 70-140 mg/dL
    Beck, Roy W.
    Raghinaru, Dan
    Calhoun, Peter
    Bergenstal, Richard M.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2024, 26 (03) : 151 - 155
  • [19] A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72
    Beck, Roy W.
    Kanapka, Lauren G.
    Breton, Marc D.
    Brown, Sue A.
    Wadwa, R. Paul
    Buckingham, Bruce A.
    Kollman, Craig
    Kovatchev, Boris
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 (05) : 329 - 342
  • [20] Beck Roy W, 2019, J Diabetes Sci Technol, V13, P614, DOI 10.1177/1932296818822496